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Abstract
Objective—As the utility of Child-Pugh (C-P) class is limited by the subjectivity of ascites and 
encephalopathy, we evaluated a previously established objective method, the albumin-bilirubin 
(ALBI) grade, as a prognosticator for yttrium-90 radioembolization (RE) treatment for patients 
with hepatocellular carcinoma (HCC).
Materials and Methods—A total of 117 patients who received RE for HCC from 2 academic 
centers were reviewed and stratified by ALBI grade, C-P class, and Barcelona Clinic Liver Cancer 
stage. The overall survival (OS) according to these 3 criteria was evaluated by Kaplan-Meier 
survival analysis. The utilities of C-P class and ALBI grade as prognostic indicators were 
compared using the log-rank test. Multivariate Cox regression analysis was performed to identify 
additional predictive factors.
Results—Patients with ALBI grade 1 (n = 49) had superior OS than those with ALBI grade 2 (n 
= 65) (P = 0.01). Meanwhile, no significant difference was observed in OS between C-P class A (n 
= 100) and C-P class B (n = 14) (P = 0.11). For C-P class A patients, the ALBI grade (1 vs. 2) was 
able to stratify 2 clear and nonoverlapping subgroups with differing OS curves (P = 0.03). 
Reprints: Salma K. Jabbour, MD, Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, 195 Little Albany St, 
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Multivariate Cox regression test identified alanine transaminase, Barcelona Clinic Liver Cancer 
stage, and ALBI grade as the strongest prognostic factors for OS (P < 0.10).
Conclusions—ALBI grade as a prognosticator has demonstrated clear survival discrimination 
that is superior to C-P class among HCC patients treated with RE, particularly within the subgroup 
of C-P class A patients. ALBI grade is useful for clinicians to make decisions as to whether RE 
should be recommended to patients with HCC.
Keywords
hepatocellular carcinoma; yttrium-90 radioembolization; prognostic indicator; albumin-bilirubin 
(ALBI) grade
The clinical prognosis and therapeutic options of patients with hepatocellular carcinoma 
(HCC) depends on both tumor burden and underlying hepatic dysfunction.1–3 The Child-
Pugh (C-P) scoring system has been widely used to measure the latter. This system was 
originally proposed to assess surgical risk in patients with portal hypertension by Child and 
Turcotte in 1964.4 In 1972, the score was modified by Pugh et al5 to include the current 5 
parameters: albumin, bilirubin, ascites, encephalopathy, and prothrombin time or 
international normalized ratio (INR). The C-P scoring system is limited due to subjectivity 
of factors including ascites and encephalopathy. In medical practice, the clinical experience 
ranges widely between novices and experienced health care providers, which affects the 
judgment of ascites and encephalopathy.6 In addition, factors including ascites and serum 
albumin levels are confounded by their interrelationship.
Johnson and colleagues introduced a new model for liver function assessment only based on 
albumin and bilirubin and termed the albumin-bilirubin (ALBI) grade. The formula for this 
scoring system relies on the following equation: ALBI score = (log10 bilirubin [µmol/L] × 
0.66) + (albumin [g/L] × −0.0852). As a result, ALBI grades 1, 2, and 3 were developed as 
follows: ALBI score ≤ −2.60 (ALBI grade 1), > −2.60 to ≤ −1.39 (ALBI grade 2), and > 
−1.39 (ALBI grade 3).7 This simple and objective model demonstrated its usefulness for 
evaluation of prognosis of HCC patients who underwent liver resection for early stage HCC 
or who were treated with sorafenib in advanced stage HCC.8–10 Patients with intermediate 
stage (eg, those treated with chemoembolization or radioembolization [RE]) were a small 
subset of the patients included in the Johnson and colleagues study.
RE is an effective therapy with a favorable toxicity profile in intermediate-stage and 
advanced-stage HCC patients.11–15 Previous studies on the prognosis of HCC patients 
receiving RE primarily focused on Okuda, C-P, Barcelona Clinic Liver Cancer (BCLC), 
Cancer of the Liver Italian Program (CLIP) score, or the TNM Staging System. The present 
study was designed to evaluate the prognostic value of ALBI grade in patients with HCC 
undergoing RE. We hypothesized that the ALBI prognostic index would serve as a better 
discriminator of overall survival (OS) for RE compared with C-P score.
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MATERIALS AND METHODS
Study Design and Eligibility Criteria
Our patient database was reviewed for patients with HCC treated with RE from June 2007 to 
January 2015 at 2 separate institutes. Pretherapeutic baseline medical history, laboratory 
values, treatment method and dosage, and survival were obtained retrospectively. All 
patients were scheduled for routine follow-up on site every month in first 3 months then 
every 3 months afterwards, including laboratory values, computed tomography/magnetic 
resonance imaging, and performance status. Patients’ date of death and cause of death were 
reported to the institutes. Death from noncancer cause was considered to be censored in the 
survival analysis.
Patients were selected to receive RE if they demonstrated an ECOG performance status from 
0 to 3, alanine transaminase (ALT) < 400 IU/L, AST < 400 IU/L, total bilirubin < 2 mg/dL. 
Two patients whose total bilirubin values were more than 2 mg/dL (2.2 and 2.6 mg/dL) also 
received RE under the clinicians’ decision. Before RE delivery, multidisciplinary consensus 
was reached to evaluate the patients’ conditions and make therapeutic decisions. Included 
patients were not operative candidates. All patients were first-time treated with yttrium-90 
resin microspheres when enrolled. This retrospective study received institutional review 
board authorization and was compliant with the Health Insurance Portability and 
Accountability Act.
Patients and Evaluation
A total of 122 patients received RE, and 5 patients were excluded because of missing 
baseline albumin or total bilirubin and according to the criteria introduced above. Baseline 
characteristics were collected within 1 week before radiation therapy. Baseline laboratory 
tests including complete blood count, liver function tests, INR, and α-fetoprotein level 
(AFP) were collected. Baseline computed tomography scans of the abdomen and chest were 
analyzed to evaluate tumor burden, volume, and vascular invasion. Baseline functional 
performance status was evaluated according to ECOG criteria.
Radiation Treatment
Patients were treated with resin-based microsphere beads (SIR-Spheres; Sirtex Medical, 
Lane Cove, Australia) or glass microspheres loaded with yttrium-90 (TheraSpheres; MDS 
Nordion, Kanata, ON, Canada). Pretreatment mesenteric angiography and technetium-99m 
macroaggregated albumin scanning (99mTC-MAA) were performed before RE to assess for 
gastrointestinal arterial supply (with identification of anatomic variants and prophylactic 
embolization of vessels if necessary) and for lung shunting. RE was performed 2 to 4 weeks 
following 99mTC-MAA scan using the methods outlined by Salem and Thurston.16 Resin-
based yttrium-90 microspheres were dosed based on tumor volumetry and total body surface 
area (BSA): activity (GBq) = (BSA − 0.2) + tumor volume/total liver volume, where BSA 
(m2) = 0.20247 × height (m)0.725 × weight (kg)0.425; whereas glass yttrium-90 microspheres 
were dosed based on infused liver volume: activity (GBq) = nominal target dose (Gy) × liver 
mass for planning target volume (kg)/50.17 The prescribed dose was administered into the 
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proper hepatic artery for bilobar treatment, left or right hepatic artery for unilobar. Two 
consecutive treatments within 8 weeks were considered as sequential treatment.16,18
Postradiation Treatments
The subsequent treatments patients received after RE were recorded, including sorafenib, 
transarterial chemoradioembolization, bland embolization, and liver transplantation.
Postradiation Toxicities
Clinical and laboratory adverse events were noted either during regular visits or through 
patient reports within 90 days after RE treatment. Toxicities were graded according to the 
National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE) 
v4.0.19
Statistics
Patients were stratified into 3 classes according to the ALBI formula previously described: 
ALBI score = (log10 bilirubin [µmol/L] × 0.66) + (albumin [g/L] × −0.0852). ALBI grades 
1, 2, and 3 were stratified as follows: ALBI score ≤ − 2.60 (ALBI grade 1), > −2.60 to ≤ 
−1.39 (ALBI grade 2), and > −1.39 (ALBI grade 3).7 Patients’ baseline characteristics 
among 3 ALBI groups were presented. Owing to baseline characteristics required for receipt 
of RE (eg, most patients’ total bilirubin < 2 mg/dL), only 3 patients were ALBI grade 3 and 
were excluded from the following statistical analysis. We compared patients’ baseline 
characteristics between ALBI grade 1 and 2 groups using Wilcoxon rank sum test for 
continuous variables and χ2 test for categorical variables. Toxicities among different ALBI 
grades were listed and compared using Fisher exact test. OS was evaluated by Kaplan-Meier 
survival analysis. Medians and 95% confidence intervals (CI) were also presented. Utilities 
of C-P class and ALBI grade as prognostic indicators were compared using log-rank test and 
C-index which is, when outcome is time-event, a generalization of the area under the 
receiver-operating characteristic curve. C-index measures the degree of discrimination: the 
higher C-index, the higher discrimination.20 P value < 0.05 was considered statistically 
significant. Univariate and multivariate Cox regression analyses were performed to look for 
potential prognosticators cooperating with ALBI grade. Significant factors in univariate 
regression analysis (P < 0.05) and factors of interest (ALBI grade, BCLC, and C-P class) 
were taken into backward multivariate regression analysis (elimination level = 0.10). Only 
factors with P values < 0.10 would stay in the final model because the sample size was 
small. To better interpret their influence on mortality in univariate and multivariate Cox 
regression analyses, certain continuous variables (AST, ALT, and AFP) were dichotomized 
into low levels and higher levels according to their medians as cutoffs. All statistical 
analyses were performed using SAS University Edition for Windows version (SAS Institute 
Inc., Cary, NC) and R packages survival and compare C available on CRAN at http://cran.r-
project.org.
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RESULTS
Descriptive Characteristics
A total of 117 HCC patients (median age 65.6 y old, 24 females, 93 males) who underwent 
RE were included. According to ALBI grade classification, patients were divided into 3 
groups: ALBI grade 1 (n = 49, 41.9%), ALBI grade 2 (n = 65, 55.6%), and ALBI grade 3 (n 
= 3, 2.6%). All patients had similar baseline characteristics except ALT, AST, albumin, 
bilirubin, ascites, INR, and C-P class (Table 1). According to C-P classification, patients 
were classified as C-P class A (n = 100, 85.5%) and C-P class B (n = 17, 14.5%). According 
to BCLC classification, patients were classified as BCLC stage A (n = 15, 12.8%), BCLC 
stage B (n = 53, 45.3%), and BCLC stage C (n = 49, 41.9%).
Grade 2/3 and Grade 4/5 Toxicities
Toxicities among 3 ALBI grades are listed in Table 2. There were 9 (7.7%) grade 2/3 
adverse events and 8 (6.8%) grade 4/5 adverse events overall. Among those 8 grade 4/5 
adverse events, 4 patients died from corresponding adverse events with 90 days (2 from 
hepatic bleeding, 2 from hepatic failure). Among 3 ALBI grades, there was no significant 
difference of grade 2/3 adverse events (P = 0.79), grade 4/5 adverse events (P = 0.57), or 
total adverse events (P = 0.63).
OS
ALBI revealed 2 classes with different prognoses for patients treated with RE. Patients with 
ALBI grade 1 had an improved survival over ALBI grade 2 (P = 0.01, Kaplan-Meier curves 
shown in Fig. 1) with median survival time of 16.7 months (95% CI, 12.3–56.9 mo) 
compared with those with ALBI grade 2 who demonstrated a median survival of 9.8 months 
(95% CI, 7.3–13.2 mo). The C-index for ALBI was 0.581. Meanwhile, no significant 
difference in OS was observed between C-P class A and C-P class B (P = 0.11, Kaplan-
Meier curves shown in Fig. 1) for which C-P class A demonstrated a median survival time of 
13.2 months (95% CI, 9.7–15.7 mo) and C-P class B had a median survival of 10.4 months 
(95% CI, 3.1–14.0 mo). The C-index for C-P was 0.545. There were significant differences 
observed in OS between BCLC stage A and B (P = 0.02) and between BCLC stage A and C 
(P < 0.01), but no significant differences observed in OS between BCLC stage B and C 
(BCLC stage B: 13.0 mo; 95% CI, 8.1–15.6 mo; BCLC stage C: 10.4 mo; 95% CI, 7.2–13.8 
mo; P = 0.28; C-index for BCLC 0.575). However, the median survival time of BCLC stage 
A was not reached because of its low patient number and highly censored observation 
number.
Survival was stratified stepwise by C-P class, and then by ALBI grade or C-P score. For C-P 
class A patients, 2 non-overlapping groups of ALBI grade 1 and 2 were revealed (P = 0.03; 
C-index 0.572; Kaplan-Meier curves shown in Fig. 2). Median survival for ALBI grade 1 
was 16.7 months; 95% CI, 12.3–56.9 months; whereas median survival for ALBI grade 2 
was 10.8 months; 95% CI, 7.6–13.8 months. In contrast, C-P score 5 versus 6 had no 
significant difference in terms of OS (P = 0.11; C-index = 0.545; Kaplan-Meier curves 
shown in Fig. 2). Median survival for C-P score 5 was 14.5 months; 95% CI, 11.9–25.0 
months; whereas C-P score 6 was 9.8 months; 95% CI, 7.6–15.0 months. For C-P class B 
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patients, neither ALBI grade nor C-P score was able to discriminate subgroups with different 
OS (P= 0.57 and 0.17, respectively).
Patients were stratified by BCLC stage first, then survival was compared between C-P class 
and ALBI grade. Within each BCLC stage, neither C-P class nor ALBI grade distinguished 
the survival time except that OS of C-P class A and B revealed a significant difference in 
patients with BCLC stage C (P = 0.01; median of C-P class A: 12.3 mo, median of C-P class 
B: 4.0 mo).
Univariate Cox regression analysis suggested that ALBI grade, BCLC, AFP, ALT, AST, 
tumor volume percentage, and portal vein invasion were correlated with OS (P values < 
0.05) (Table 3). On multivariate analysis, ALBI grade, BCLC, and ALT remained survival 
prognosticators (P values < 0.10) (Table 4).
DISCUSSION
Our data revealed that ALBI grade had a superior ability to discriminate the prognosis of 
HCC patients treated with RE, whereas C-P class was not able to clearly predict for OS. The 
degree of discrimination by ALBI grade was better than C-P class both graphically and on 
formal statistical analysis. The C-index for ALBI grade was slightly greater than that for C-P 
class.
In a recent study by Hickey et al,21 765 HCC patients treated with RE and 
chemoembolization were independently divided into ALBI grade 2 and grade 3 with a 
significant survival difference. The majority of patients in the study were C-P class B and 
were stratified into 2 groups according to ALBI grade. In contrast, our patients generally had 
preserved hepatic function with a normal total bilirubin and C-P class A classification at the 
onset of treatment. Most of patients in the present study were successfully stratified by 
ALBI grade within C-P class A. This demonstrates the versatility of ALBI grade 
discrimination across both C-P class A and C-P class B patients. On the basis of our 
outcome and the Hickey et al, outcome together, ALBI grade is a promising prognostic 
factor that can be used widely in HCC patients treated with RE.
C-P class includes 3 parameters that do not directly contribute to ALBI grade—INR, ascites, 
and encephalopathy. However, distributions of INR and ascites were correlated with ALBI 
grade. The relationship of ALBI grade with encephalopathy was limited by the low rates of 
encephalopathy in this study; all 5 patients with encephalopathy had an ALBI score of 2 but 
this did not reach statistical significance (P = 0.07). These results attest to the overlap of 
hepatic function parameters (ascites, INR, encephalopathy) as prognosticators. Although 
ALBI grade is composed only of albumin and bilirubin, it had a good capacity to reveal the 
impact of liver function on survival time. It therefore may be preferred to avoid the 
subjectivity of characterizing ascites and encephalopathy, which are sources of potential 
error in the C-P system.
Liver function and tumor burden are 2 different factors that impact OS. These 2 factors are 
also correlated, and patients with high tumor burden may have resulting decline in liver 
function in excess of baseline hepatic dysfunction. In the multivariate analysis, tumor 
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volume failed to independently predict OS. On the contrary, ALT which also suggests liver 
function demonstrated its prognostic ability. Further studies with detailed causes of death 
might uncover whether the mortality is associated with liver function failure or tumor 
burden.
Another prognostic factor is BCLC stage which has been commonly used to stratify and 
select HCC patients for different therapeutic strategies.22 BCLC staging consists of 
performance status, C-P score, tumor size, number of tumors, vascular invasion, nodal 
spread, and extrahepatic metastases. BCLC stage includes both liver function and tumor 
burden simultaneously, and helps to define treatments that are indicated for the patient. By 
the definition, BCLC stage A (early stage), stage B (intermediate stage), and stage C 
(advanced stage) share the same live function characteristic—C-P class A or B. However, as 
we reported earlier, C-P class was not able to clearly predict for OS. ALBI grade might be a 
promising substitute of C-P class in BCLC stage.
Patients with ALBI grade 2 had the highest rate of adverse events (18.4%). Even though no 
statistically significant difference of overall adverse events was found between different 
ALBI grades, a higher ALBI grade seemed to show a higher number of liver-related 
complications. As for CTCAE grade 2/3 liver-related complications, patients with ALBI 
grade 1 presented fewer than ALBI grade 2 complications (n = 1 encephalopathy vs. n = 4 
total including encephalopathy and ascites). High-grade liver-related complications (CTCAE 
grade 4/5) were less frequent in patients with ALBI grade 1 than ALBI grade 2 (n = 1 
hepatic failure vs. n = 6 total including hyperbilirubinemia, hepatic failure, and hepatic 
bleeding). A larger population with a more robust analytical power to examine the 
relationship between ALBI grade and liver-related complications would be useful for future 
study.
This study included patients receiving health care in 2 large medical centers, which ensured 
high quality of follow-up, comprehensiveness of analysis factors, and consensus of data 
(tested in Table 1). We analyzed a novel and promising predictor that is more objective than 
the conventional C-P class. Our data provided a supplement to the results reported by 
Hickey and colleagues who stratified between ALBI grade 2 and 3, but were unable to 
illustrate differences between survivals for ALBI grade 1 and 2, and between these 2 groups 
within C-P class A. Our finding of 2 distinct subpopulations (ALBI grade 1 and 2) within C-
P class A with different OS correlates with the findings of Johnson et al in their initial 
discussion of the ALBI grade. More importantly, we addressed how the ALBI grade 
performs in comparison with C-P score within a given C-P class. Johnson and colleagues did 
not have access to C-P scores, and therefore could not answer this question. We found that 
even though C-P score 5 and 6 seemed to graphically stratify the survival curves of C-P class 
A, this difference was not statistically significant. However, ALBI grade successfully 
demonstrated this capacity and revealed a higher discrimination degree than C-P score did 
within C-P class A patients.
Because of the criteria of patients inclusion for RE (total bilirubin < 2 mg/dL), this study 
was limited by the small proportion of C-P class B patents (n = 17, 14.5%) and ALBI grade 
3 patients (n = 3, 2.6%), which set a barrier for the analysis of patients with poor liver 
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function. Patients mostly had well-compensated cirrhosis (C-P class A, n = 100, 85.5%) 
which might compromise the discrimination ability of C-P class. In addition, as a 
consequence of a small sample size in each category, ALBI grade failed to break down the 
survival in any subgroups stratified by BCLC stage. The same reason was considered to 
explain why ALBI failed to demonstrate a P value < 0.05 (P value = 0.06) in multivariate 
analysis.
In summary, ALBI grade is an objective prognosticator for liver function and has shown 
survival discrimination of HCC patients treated with RE that is superior to C-P class. Our 
study delineates the ability of ALBI grade to discriminate 2 subpopulations within C-P class 
A. ALBI grade is a promising indicator for predicting the prognosis of patients with HCC; 
therefore, it can play a role in guiding treatment options including RE. Further research 
incorporating ALBI grade into an existing staging system might give rise to a more concise 
and robust prediction system.
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FIGURE 1. 
Overall survival in months after radioembolization stratified by albumin-bilirubin (ALBI) 
grade (P = 0.01; C-index between ALBI grade 1 and 2 = 0.581) and Child-Pugh class (P = 
0.11; C-index = 0.545).
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FIGURE 2. 
Child-Pugh (C-P) class A patient survival in months for radioembolization according 
albumin-bilirubin (ALBI) (P = 0.03; C-index = 0.572) and C-P score (P = 0.11; C-index = 
0.545).
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TABLE 3
Univariate Cox Regression Analysis
Characteristics
Hazard
Ratio
95% Confidence
Interval P
Sex 0.72 0.40–1.29 0.27
Age (y) 1.01 0.99–1.03 0.43
ALBI grade 2 vs. 1 1.78 1.12–2.84 0.01
BCLC stage B vs. A 2.85 1.10–7.35 0.03
BCLC stage C vs. A 3.72 1.46–9.48 < 0.01
Child-Pugh class 1.68 0.89–3.19 0.11
Tumor volume (%) 4.87 1.57–15.04 < 0.01
Portal vein invasion yes vs. no 1.63 1.02–2.57 0.04
AST > 80 vs. ≤ 80 (IU/L) 1.91 1.21–3.03 < 0.01
ALT > 63 vs. ≤ 63 (IU/L) 1.72 1.10–2.72 0.02
AFP > 144 vs. ≤ 144 (ng/mL) 1.79 1.14–2.83 0.01
AFP indicates α-fetoprotein level; ALBI, albumin-bilirubin; ALT, alanine transaminase; AST, aspartate transaminase; BCLC, Barcelona Clinic 
Liver Cancer.
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TABLE 4
Multivariate Backward Cox Regression
Analysis Characteristics Hazard Ratio P
ALBI grade 2 vs. 1 1.62 0.06
BCLC B vs. A 3.17 0.03
BCLC C vs. A 4.10 0.01
ALT > 63 vs. ≤ 63 (IU/L) 1.67 0.046
Elimination level = 0.10.
AFP indicates a-fetoprotein level; ALBI, albumin-bilirubin; ALT, alanine transaminase; AST, aspartate transaminase; BCLC, Barcelona Clinic 
Liver Cancer.
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